Baseret på post- marketing erfaring er en bivirkning, herunder hypoglykæmi, sjældent rapporteret (> 1/ 10. 000 < 1/ 1. 000).
Based on post-marketing experience adverse drug reactions including hypoglycaemia have been reported rarely (> 1/ 10,000 < 1/ 1,000).